MyoKardia Company Profile (NASDAQ:MYOK)

Analyst Ratings

Consensus Ratings for MyoKardia (NASDAQ:MYOK) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.50 (38.81% upside)

Analysts' Ratings History for MyoKardia (NASDAQ:MYOK)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2016BMO Capital MarketsInitiated CoverageOutperform$3.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Credit Suisse Group AGReiterated RatingBuy$16.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016WedbushReiterated RatingOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for MyoKardia (NASDAQ:MYOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q1($0.53)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2016Q4($0.68)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MyoKardia (NASDAQ:MYOK)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.34)($0.34)($0.34)
Q3 20161($0.35)($0.35)($0.35)
Q4 20161($0.18)($0.18)($0.18)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.23)($0.23)($0.23)
Q3 20171($0.19)($0.19)($0.19)
Q4 20171$0.17$0.17$0.17
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MyoKardia (NASDAQ:MYOK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MyoKardia (NASDAQ:MYOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for MyoKardia (NASDAQ:MYOK)
DateHeadline
07/14/16 08:57 AMSHaRe Registry Data Published in PNAS Demonstrate the Power of Combining ...
07/14/16 07:38 AMSHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy - [at noodls] - SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable ...
07/12/16 12:09 PMHere’s What To Look For Ahead Of The Myokardia Inc (MYOK) Phase II -
07/11/16 03:13 PMMYOKARDIA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/11/16 03:13 PMMyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients - [at noodls] - MYK-461 Data Suggest Favorable Safety Profile Up to 28 Days Dosing in Healthy Volunteers and Reduction in Excess Cardiac Contractility in All HCM Patients Studied Company Plans to Initiate Phase 2 PIONEER-HCM ...
06/28/16 08:16 AMMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : June 28, 2016 -
06/16/16 05:30 PMCetera Financial Group :'s Parent Company Completes Board with Addition of Industry Leading Executives
06/16/16 05:30 PMCetera Parent Company Completes Board Of Directors
06/08/16 03:24 PMMYOKARDIA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/16/16 06:42 AMMyoKardia to Present at 2016 UBS Global Healthcare Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable ...
05/12/16 09:32 AMTherapy for obstructive hypertrophic cardiomyopathy receives orphan drug designation - MyoKardia Inc. announced that the FDA has granted an orphan drug designation to its novel drug for treatment of symptomatic obstructive hypertrophic cardiomyopathy. The drug (MYK-461) is the first therapy developed to target the underlying cause of ...
05/12/16 09:32 AMMYOKARDIA INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - 01:31p MyoKardia Reports First Quarter 2016 Financial Results and Operational Progre.. 05/03 MYOKARDIA: Receives Orphan Drug Designation for MYK-461 for Treatment of Sympto.. 05/02 MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Sympt.
05/12/16 06:57 AMMyoKardia Reports First Quarter 2016 Financial Results and Operational Progress - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable ...
05/12/16 06:43 AMMyoKardia reports 1Q loss -
05/03/16 09:25 AMMyoKardia (MYOK) Announces Receipt of Orphan Drug Designation for MYK-461 for Treatment of Symptomatic oHCM - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. MyoKardia, Inc. (Nasdaq: MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases ...
05/02/16 10:05 AMMyoKardia Gets Orphan Drug Designation For MYK-461 For Treatment Of OHCM - (RTTNews.com) - MyoKardia, Inc. ( MYOK), a clinical stage biopharmaceutical company for the treatment of heritable cardiovascular diseases, announced Monday that the U.S. Food and Drug Administration has granted the company Orphan Drug Designation for MYK ...
05/02/16 06:30 AMMyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., May 02, 2016-- MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
04/15/16 09:30 AMPCSK9 Inhibitors for Statin Intolerance, Early Beta Blockade in AMI Debated - Inc.; MyoKardia; Orexigen Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Regado Biosciences; Sanofi; WebMD Received grants for clinical research from: American College of Cardiology; American Heart Association; National Heart, Lung, and Blood Institute ...
04/13/16 06:43 AMMyoKardia Names Mary Cranston to Board of Directors - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 13, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable ...
03/24/16 12:04 PMMYOKARDIA INC Financials -
03/22/16 02:00 PMMyoKardia, Inc. :MYOK-US: Earnings Analysis: 2015 By the Numbers -
03/19/16 08:19 AMMyoKardia : reports 4Q loss - SOUTH SAN FRANCISCO, Calif. (AP) _ MyoKardia Inc. (MYOK) on Friday reported a loss of $7.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 48 cents. The biopharmaceutical company ...
03/18/16 08:17 AMMYOKARDIA : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Item 2.02 Results of Operations and Financial Condition. On March 18, 2016, MyoKardia, Inc. announced its financial results for the fourth quarter and year ended December 31, 2015. The full text of the press release issued in connection with the ...
03/18/16 07:32 AMMYOKARDIA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/18/16 06:43 AMMyoKardia reports 4Q loss -
03/18/16 06:30 AMMyoKardia Reports Fourth Quarter and 2015 Financial Results and Key Milestones - [GlobeNewswire] - -Lead product candidate demonstrates clinical proof of mechanism in hypertrophic cardiomyopathy patients; Phase 2 planned for second half of 2016. -Growing evidence in nonclinical studies that MYK-461 ...
03/17/16 08:40 AMSanofi pledges potential $2.26B for next-gen oral drugs - For example, in 2014 Sanofi inked a similar, though smaller, deal with Third Rock Ventures-backed Myokardia Inc. for three discovery-stage assets targeting hypertrophic cardiomyopathy and dilated cardiomyopathy. (See BioWorld Today, Sept. 18, 2014.)
03/11/16 05:10 AM5 Breakout Stocks to Buy Off Weakness -
03/08/16 05:10 AMMYOKARDIA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
03/07/16 06:30 AMMyoKardia Names Sunil Agarwal, M.D., to Board of Directors, New VPs Strengthen Research and Development - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 07, 2016-- MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
03/06/16 07:48 AM$100 Billion French Pharma Giant Sanofi says they’re on the “Hunt” for Rare Disease Acquisitions: Here’s who they may be Eyeballing - One of the more obvious companies that Sanofi may look to is one where they already have money at work. MyoKardia, Inc. (NASDAQ: MYOK) is a company with an initial focus on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven ...
03/01/16 07:00 AMMyoKardia to Present at Cowen and Company 36th Annual Health Care Conference - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 01, 2016-- MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
02/29/16 04:54 PMPrecision Medicine Prevents Common Cardiovascular Disease in Mice - Clinical stage biopharmaceutical company MyoKardia Inc., developed the small molecule and the published research is a collaboration of the company, Stanford University, Harvard Medical School and the University of Colorado. The researchers performed tests ...
02/23/16 10:33 AMMYOKARDIA INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Stat -
02/23/16 07:00 AMMyoKardia Announces Transition of Chief Medical Officer - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Feb. 23, 2016-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
02/18/16 04:41 PMRedwood City startup snags $45M to take on deadly lung disease - Three of its companies — MyoKardia Inc., Global Blood Therapeutics Inc. and CytomX Therapeutics Inc., all of South San Francisco — went public last year. Third Rock has continued to pour cash into post-recession startups as well, including Revolution ...
02/11/16 07:21 AMIWN's Underlying Holdings Could Mean 27% Gain Potential - Three of IWN's underlying holdings with notable upside to their analyst target prices are Westmoreland Coal Co. (WLB), MyoKardia Inc (MYOK), and Dimension Therapeutics Inc (DMTX). Although WLB has traded at a recent price of $4.80/share, the average ...
02/08/16 04:26 PMSudden cardiac death may soon be a thing of past - Now, a team of scientists from Harvard Medical School, Stanford University School of Medicine, University of Colorado, and MyoKardia Inc. in San Francisco, a biotechnology company formed to develop such treatments, has used some of Warshaw's earlier ...
02/08/16 07:03 AMPioneering Discovery Could Lead to Preventive Treatment for Sudden Cardiac Death - The team of scientists who found a way to address this problem - which they report in Science - are from Harvard Medical School, Stanford University School of Medicine, University of Colorado, and MyoKardia Inc. in San Francisco, a biotechnology company ...
02/07/16 06:59 AMStaving off sudden heart death may soon be possible - Now, scientists from Harvard Medical School, Stanford University School of Medicine, University of Colorado and MyoKardia Inc. has used some of Warshaw's earlier findings to develop a possible treatment to prevent hypertrophic cardiomyopathy (HCM), an ...
02/07/16 06:59 AMScientists find potential treatment for sudden cardiac death - Now, a team of scientists from Harvard Medical School, Stanford University School of Medicine, University of Colorado, and MyoKardia Inc. in San Francisco, a biotechnology company formed to develop such treatments, has used some of Warshaw's earlier ...
02/05/16 04:25 PMPioneering discovery leads to potential preventive treatment for sudden cardiac death - The team of scientists who found a way to address this problem - which they report in the February 5, 2016 issue of Science - are from Harvard Medical School, Stanford University School of Medicine, University of Colorado, and MyoKardia Inc. in San ...
02/05/16 12:24 PMMYOKARDIA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
02/04/16 04:27 PMMyoKardia Science article demonstrates MYK-461 prevents and reverses disease in HCM mice - MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the leading medical journal Science. The article ...
02/04/16 04:27 PMSupports Therapeutic Hypothesis Linking Reduction in Sarcomere Power Output to Improvements in Structural Pathology of HCM - February 04, 2016 14:00 ET | Source: MyoKardia, Inc. SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...
02/04/16 04:27 PMMyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in - SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the ...
02/04/16 01:03 PM2:03 pm MyoKardia publishes article in medical journal 'Science' which demonstrates the ability of MYK-461 to prevent and reverse development of disease in multiple genetic mouse models of hypertrophic cardiomyopathy -
02/04/16 01:00 PMMyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016-- MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
01/25/16 06:44 AMReport Published: "Hypertrophic Cardiomyopathy Global Clinical Trials Review, H2, 2015" - Companies Mentioned in this Report: Gilead Sciences, Inc., Heart Metabolics Limited, MyoKardia, Inc., Spaulding Clinical Research, LLC, Quintiles Transnational Holdings Inc., Physicians' Services Incorporated Foundation, Novartis AG, Katakura Industries Co ...
10/29/15 08:16 AMToday's Bell Ringer, October 29, 2015 -

Social

About MyoKardia

MyoKardia logoMyoKardia, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). In addition, the Company is evaluating MYK-461 and initiated a Phase I clinical program for the treatment of HCM.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MYOK
  • CUSIP:
Key Metrics:
  • Previous Close: $16.93
  • 50 Day Moving Average: $14.01
  • 200 Day Moving Average: $11.24
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $457.80M
  • Current Year EPS Consensus Estimate: $-1.24 EPS
  • Next Year EPS Consensus Estimate: $-1.73 EPS
Additional Links:
MyoKardia (NASDAQ:MYOK) Chart for Tuesday, July, 26, 2016